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To determine vaccine coverage of invasive pneu-
mococcal disease (IPD) in Saudi Arabian children
aged 5 years and under, 350 IPD isolates were
tested for antibiotic susceptibility. Of these 46%,
42% and 12% were penicillin-sensitive, pencillin-
intermediate, and penicillin-resistant, respec-
tively. Rates of resistance to erythromycin and
cefotaxime were 26% and 6%, respectively. The
potential serotype coverage of the PCV7 vaccine
in Saudi Arabia among children <5 years of age
is 62%, and vaccine coverage significantly
improved in children <2 years of age, to reach
83% against IPD isolates. PCV7 is expected to
have a substantial impact on the burden of
invasive and antibiotic-resistant pneumococcal
disease in Saudi Arabia.
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Streptococcus pneumoniae is one of themost common
bacterial causes of morbidity and mortality world-
wide, causing life-threatening infections such as
meningitis, pneumonia and febrile bacteraemia
[1,2]. The WHO reports that one million children,
mostly young and living in developing countries,
die from pneumococcal disease annually [3]. The
severity and frequency of S. pneumoniae infection,
as well as the emergence of drug-resistant isolates,
has led to renewed emphasis on the prevention of
pneumococcal disease.
A seven-valent conjugate vaccine (PCV7) (sero-
types 4, 6B, 9V, 14, 18C, 19F and 23F), which was
first introduced in the USA [4–6], is now licensed
throughout the world. Before introduction of
PCV7 into the national immunization pro-
gramme, invasive pneumococcal disease (IPD)
had resulted in 175 000 hospitalizations and up to
12 500 deaths annually in the USA [7]. The
vaccine now offers protection against seven of
the more than 90 pneumococcal capsular sero-
types, and includes those serotypes responsible
for most infections in industrialized countries [5].
Because of geographical variations in serotype
distribution, the vaccine may not be universally
optimal, and knowledge of regional pneumococcal
serotype distribution is therefore needed to eval-
uate the potential impact of vaccination in a
population being immunized. The present study
was undertaken to determine the serotype distri-
bution of invasive S. pneumoniae isolated from
children across Saudi Arabia and to correlate this
distribution with susceptibility to penicillin,
erythromycin and cefotaxime.
In total, 350 invasive S. pneumoniae isolates
were collected between 2000 and 2004 by 25
microbiology laboratories throughout Saudi Arabia
and was sent to King Saud University for char-
acterization. Participating laboratories were non-
randomly selected, to be as representative as
possible of a wide range of patient demographics
and diverse geographical locations, from both
hospitals and community-based laboratories
throughout Saudi Arabia. It was estimated that
these hospitals provided inpatient services to
approximately half the population.
All isolates were confirmed as S. pneumoniae e
by colony morphology and haemolysis on
blood agar plates, and by optochin sensitivity
and bile solubility testing. The incidence rate of
IPD was not calculated, because the isolates
represented only a sample of all the invasive
isolates during the study period.
Serotyping was performed by the standard
capsular reaction test with the chessboard system
and specific sera (Statens Serum Institute, Copen-
hagen, Denmark) [8]. All isolates were tested for
antibiotic sensitivity against penicillin, erythro-
mycin and cefotaxime using Etest strips (AB
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Biodisk, Solna, Sweden) according to the manu-
facturer’s instructions and Mueller–Hinton
agar supplemented with 5% sheep blood. The
breakpoints recommended by the CLSI were used
to interpret MIC values [9]. MIC value categories
used for penicillin were as follows: sensitive,
0.01–0.1 mg ⁄L; intermediate, 0.1–1.0 mg ⁄L; and
resistant, ‡2 mg ⁄L [9]. Quality control strains
(S. pneumoniae e ATCC 49619) were included
with each run. Multidrug resistance was defined
as resistance to the three antibiotics tested.
During the study period, 82% of the invasive
isolates were recovered from blood and 18% from
cerebrospinal fluid and other normally sterile
fluids. Approximately 45% were isolated from
children aged <2 years.
All invasive isolates were serotyped, with
c. 15% (51, 14.6%) of them being non-typeable
(omni-serum-positive, but pool-specific-negative
and factor-specific sera-negative).
Table 1 shows the most common serotypes
found among the invasive isolates from children
aged <5 years. In children <2 years of age, sero-
types 14, 23F, 6B and 19F were the most
prevalent. Overall, 62% of isolates from all age
groups and 83% of isolates from children aged
<2 years were represented in PCV7. Serotypes
of invasive S. pneumoniae e in relation to PCV7
serotypes are shown in Table 1.
Most invasive isolates collected from children
<5 years of age had decreased susceptibility to
penicillin, with 54% of the isolates being resistant
to penicillin; 42% had intermediate resistance,
and 12% were fully resistant. The frequency of
resistance among invasive serotypes included in
PCV7 is shown in Table 2.
Resistance to a third-generation cephalosporin
(cefotaxime) was low (6%). Approximately 18%
of the penicillin-resistant isolates were also resis-
tant to erythromycin. Approximately 60% of the
isolates were resistant to at least one of the three
antibiotics tested. Four serotypes (6B, 19F, 23F
and 14) accounted for 80% of the invasive isolates
with resistance to one or more of the antibiotics
tested (penicillin, erythromycin and cefotaxime).
Five isolates (all serotype 19F) with penicillin
MICs >8 mg ⁄L were encountered.
Recent local studies in Saudi Arabia have
shown that almost 60% of S. pneumoniae e isolates
are non-susceptible to penicillin (46% penicillin-
intermediate and 18% penicillin-resistant) [10].
This may be partially due to the misuse of
antibiotics within the country, as antibiotics can
be purchased without a prescription. Rates of
resistance to macrolides, chloramphenicol and
trimethoprim–sulphamethoxasole are 29%, 14%
and 62%, respectively [10]. Local data further
reveal that Saudi Arabia has four predominant
clones, namely of serotypes 19F, 6B, 18C and 23F,
which have been associated previously with
decreased susceptibility to penicillin [11].
Previously published studies [12, 13] have
shown that penicillin resistance in pneumococci
isolated from children who are carriers is c. 18%
in Saudi Arabia.
The potential serotype coverage of PCV7 in
Saudi Arabia among children <5 years of age
is 62%, and vaccine coverage significantly
improved in children aged <2 years of age to
reach 83% against IPD isolates. A recent study on
serotypes from IPD patients in Riyadh, based on
75 isolates, has been reported [14]. Although it
was found that serotypes 14, 23F and 4 were
predominant, only a few isolates were from
children <5 years of age [14].
Most penicillin-resistant isolates belonged to
serogroups 9, 14, 19 and 23 and were also
multiresistant. In contrast, intermediate resistance
was found in other serotypes [15]. The finding
that PCV7 included serotypes that accounted for
the majority of the least penicillin-susceptible, as
Table 1. Frequency of different serotypes among the 350
invasive isolates collected from 25 Saudi hospitals between












14 35 18 2 55
23F 31 13 2 46
6B 24 8 4 36
19F 19 8 4 31
18C 11 6 3 20
9V 7 9 2 18
4 5 4 2 11
VST 132 (83.0) 66 (62.3) 19 (22.4) 217 (62)
19A 3 1 2 6
3 2 1 4 7
24 2 3 2 7
15 2 – 4 6
6A 1 1 4 6
23A 1 2 3 6
7 1 2 3 6
11 1 4 1 6
23B 1 1 3 5
5 1 2 2 5
22 1 3 – 4
12 – 1 6 7
8 – 1 5 6
1 – 3 2 5
NVST 16 (10.1) 25 (23.6) 41 (48.2) 82 (23.4)
Non-typeable 11 (6.9) 15 (14.1) 25 (29.4) 51 (14.6)
Total 159 106 85 350
VST, vaccine serotype; NVST, non-vaccine serotype.
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well as the multidrug-resistant, pneumococci is
encouraging. Therefore, the vaccine could
reduce the impact of penicillin-resistant strains
on invasive disease and potentially control the
rapidly emerging drug-resistant pneumococci in
this part of the world.
In conclusion, this surveillance over a period of
4 years of invasive isolates has documented the
serotype distribution and antibiotic resistance
rates in invasive isolates among Saudi children.
These data serve to substantiate the potential role
for PCV7 in Saudi Arabia. Continued surveillance
that monitors changes in serotype distribution
over timewill be important, particularly to observe
changes that may result from the introduction of
targeted or widespread vaccination programmes.
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Erythromycina, no. (%) Cefotaximea, no. (%)
S I R R R
14 20 31 4 55 13 4
23F 19 21 6 46 19 3
6B 15 14 7 36 16 4
19F 4 19 8 31 11 3
18C 7 12 1 20 5 –
9V 6 9 3 18 3 –
4 6 4 1 11 3 2
VST 77 (35.5) 110 (50.7) 30 (13.8) 217 (62.0) 70 (32.3) 16 (7.4)
19A 3 1 2 6 2 –
3 5 – 2 7 2 –
24 5 2 – 7 2 –
15 3 2 1 6 3 –
6A 1 3 2 6 3 2
23A 4 1 1 6 – 1
7 6 – – 6 – –
11 6 – – 6 – –
23B 2 2 1 5 1 –
5 4 – 1 5 1 1
22 4 – – 4 – –
12 7 – – 7 – –
8 6 – – 6 – –
1 3 1 1 5 2 1
Non-typeable 25 25 1 51 5 0
NVST 84 (63.2) 37 (27.8) 12 (9) 133 (38) 21 (15.8) 5 (3.8)
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producing Acinetobacter baumannii isolates
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A B S T R A C T
Five carbapenem-resistant Acinetobacter baumannii
isolates, collected from the United Arab Emirates
in 2006, were investigated to identify the mech-
anism(s) responsible for carbapenem resistance.
Genotyping was performed by pulsed-field gel
electrophoresis, and the location of the blaOXA-23
gene was determined by using the endonuclease
I CeuI technique and mating-out assays. The four
isolates in which the blaOXA-23 gene was located
on the chromosome within a Tn2006 composite
transposon were clonally related. The single non-
clonally related isolate harboured the blaOXA-23
gene on a 70-kb transferable plasmid. This study
reports on the dissemination of OXA-23-produc-
ing A. baumannii isolates in the Middle East.
Keywords Acinetobacter baumannii, carbapenem resis-
tance, OXA-23, transposon, United Arab Emirates
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Carbapenem resistance in Acinetobacter bauman-
nii is increasingly being observed worldwide.
Several studies have reported metallo-b-lacta-
mases (MBLs) [1], but the most common mech-
anism is related to carbapenem-hydrolyzing
class D b-lactamases (CHDLs) [2]. Three main
acquired CHDL gene clusters have been de-
scribed in A. baumannii, containing blaOXA-23-like,
blaOXA-40-like or blaOXA-58-like genes. The blaOXA-23
gene is either plasmid-borne or chromosome-
borne [3,4], and A. radioresistens was recently
identified as the progenitor of blaOXA-23-like
genes [5].
From July 2006 to November 2006, five carba-
penem-resistant A. baumannii isolates causing
fatal infections in five patients were collected
from the adult intensive-care unit of Sheikh
Khalifa Medical City. Whereas two isolates were
considered to be colonizing agents, three were
involved in infections, two of which caused
septicaemia. The age of the patients ranged from
30 to 60 years, and all of them had been treated
with colistin and tobramycin, except patient 3,
who was treated with colistin and tigecycline
(Table 1).
The isolates were identified after 16S rRNA
gene sequencing [6]. MICs of imipenem and
meropenem were determined using antibiotic
disks from Sanofi Diagnostics Pasteur (Marne-
La-Coquette, France) [7] and were found to be
32 mg ⁄L (Table 2). The isolates were resistant to
almost all antibiotics, including aminoglycosides,
fluoroquinolones and b-lactams (Table 2).
The production of MBLs was evaluated using
the MBL Etest, combining imipenem and EDTA as
recommended by the manufacturer (AB Biodisk,
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